Rescue Transcatheter Aortic Valve Implantation for Severe Native Aortic Regurgitation in a Young Patient with Hypertrophic Obstructive Cardiomyopathy and Cardiogenic Shock: Review of the Literature and Case Presentation
Current evidence on TAVI for native AR focuses on devices, procedural performance, complications, and outcomes, and presents a 24-year-old man with MYH7-associated hypertrophic obstructive cardiomyopathy and severe post-myectomy AR complicated by biventricular failure, cardiogenic shock, and multiorgan dysfunction.
Abstract
Transcatheter aortic valve implantation (TAVI) for pure native aortic regurgitation (AR) remains technically challenging, primarily because absent annular calcification limits prosthesis anchoring. We reviewed contemporary evidence on TAVI for native AR, focusing on devices, procedural performance, complications, and outcomes. A comprehensive PubMed search identified 371 articles, of which 28 studies comprising 3282 patients met the inclusion criteria; notably, 64.3% were published from 2023 onward, reflecting the rapidly expanding evidence in this field. Conventional off-label devices were evaluated in 60.7% of studies and dedicated AR devices in 35.7%, while 3.6% directly compared both strategies. Technical/device success ranged from 72% to 100%, generally exceeding 85–90% in contemporary series, while 30-day mortality ranged from 0% to 23%. To illustrate the technical challenges and expand this evidence, we present a 24-year-old man with MYH7-associated hypertrophic obstructive cardiomyopathy and severe post-myectomy AR complicated by biventricular failure, cardiogenic shock, and multiorgan dysfunction. Given prohibitive surgical risk, rescue transfemoral TAVI was performed. Despite embolization of the first balloon-expandable prosthesis, a second valve was successfully implanted using an individualized anchoring strategy. At 1 year, the patient was in NYHA class I with biventricular recovery. TAVI represents an evolving alternative for carefully selected patients with severe native AR and prohibitive surgical risk.
ABSTRACT Background Aortic regurgitation (AR) is a frequent and clinically relevant complication in patients with left ventricular assist devices (LVAD), impairing circulatory support and worsening outcomes. Surgical aortic valve replacement often carries prohibitive risk in this population, while conventional transcat...
H. Hinkov, Sara Yousefzada, I. Just et al.· Artificial Organs· 0 citations
BACKGROUND
The JenaValve Trilogy Transcatheter Heart Valve System (Trilogy) is a CE-marked transcatheter aortic valve replacement device designed for the treatment of symptomatic aortic regurgitation. Despite its unique indication, data from large cohorts remain limited. This study aimed to evaluate procedural characte...
H. Wienemann, Sara Yousefzada, M. Rogmann et al.· Circulation. Cardiovascular...· 0 citations
Introduction Transcatheter heart valve implantation into a failed surgical heart valve (THV-in-SHV) is an established reintervention strategy for degenerated aortic bioprostheses; however, early procedural outcomes, discharge hemodynamics, and standardized safety remain clinically relevant in routine practice. Material...
R. Sobczyński, J. Trębacz, Paweł Kleczyński et al.· Cardiology Journal· 0 citations
Background: Aortic valve regurgitation is a common valvular heart disease. Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are the principal therapeutic modalities, while the comparative efficacy of these two approaches remains controversial. Methods: This systematic review an...
Hong-Hong Ke, Shi-Rong Wang, Jin-Yi Li et al.· Journal of Cardiovascular De...· 0 citations
Transcatheter aortic valve implantation (TAVI) has expanded from a treatment for inoperable and high-risk aortic stenosis (AS) to an established therapeutic option for selected patients at low surgical risk; this review focuses on the outcomes of major trials comparing TAVI to traditional surgical aortic valve replacem...
Kelly Wright, Arafat Rahman, Georgia Penny et al.· Expert Review of Cardiovascu...· 0 citations
Aortic stenosis is among the most common valvular heart diseases and, if untreated, can lead to
reduced quality of life and potential heart failure. Surgical Aortic Valve Replacement (SAVR) has long
been recognized as the standard treatment for severe aortic stenosis, while Transcatheter Aortic Valve
Replacement (TAVR)...
Dev Shah· American Journal of Student...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.